Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 16, 2018 09:00 ET | Source: Biothera Pharmaceuticals, Inc.

Biothera Pharmaceuticals Presents Translational Data from Ongoing Clinical Trials Showing Imprime PGG in Combination with Merck’s KEYTRUDA® (pembrolizumab) Drives Innate and Adaptive Immune Responses in Tumors

EAGAN, Minn., April 16, 2018 (GLOBE NEWSWIRE) -- Biothera Pharmaceuticals, Inc. today announced the presentation of new translational data from ongoing phase 2 clinical trials combining Biothera’s...
February 06, 2018 09:30 ET | Source: Biothera Pharmaceuticals, Inc.

Biothera Pharmaceuticals Commences Phase 2 Head and Neck Cancer Study Evaluating Combination of Imprime PGG and Merck’s KEYTRUDA® (pembrolizumab)

EAGAN, Minn., Feb. 06, 2018 (GLOBE NEWSWIRE) -- Biothera Pharmaceuticals, Inc. announced today that patient treatment has commenced in its Phase 2 clinical study in squamous cell carcinoma of the...
November 28, 2017 09:00 ET | Source: Biothera Pharmaceuticals, Inc.

Biothera Pharmaceuticals Enters Cancer Immunotherapy Clinical Trial Collaboration Agreement

EAGAN, Minn., Nov. 28, 2017 (GLOBE NEWSWIRE) -- Biothera Pharmaceuticals, Inc. today announced that it has entered into a clinical trial collaboration agreement with Genentech, Inc., a member of the...
November 21, 2017 09:23 ET | Source: Biothera Pharmaceuticals, Inc.

Biothera Pharmaceuticals to Present at the 29th Annual Piper Jaffray Healthcare Conference

EAGAN, Minn., Nov. 21, 2017 (GLOBE NEWSWIRE) -- Biothera Pharmaceuticals, Inc. today announced that Chief Executive Officer Barry Labinger will present at the 29th Annual Piper Jaffray Healthcare...
November 13, 2017 09:30 ET | Source: Biothera Pharmaceuticals, Inc.

Biothera Pharmaceuticals Presents Data Broadening Imprime PGG Mechanism of Action

Reduces expression of IDO, a potent suppressor of an anti-cancer T cell response Supplementation with IVIG boosts biomarker levels, restoring Imprime-driven pharmacodynamic responses EAGAN, Minn.,...
October 30, 2017 09:00 ET | Source: Biothera Pharmaceuticals, Inc.

Biothera Pharmaceuticals Presents Preclinical Data Showing Imprime PGG Activates Natural Killer Cell-Mediated Tumor Killing

EAGAN, Minn., Oct. 30, 2017 (GLOBE NEWSWIRE) -- Biothera Pharmaceuticals, Inc. announced today the presentation of new preclinical findings showing that the Company’s Phase 2 cancer immunotherapy...
September 28, 2017 12:09 ET | Source: Biothera Pharmaceuticals, Inc.

Biothera Pharmaceuticals Announces Presentations on Imprime PGG at Three Upcoming Healthcare Conferences

EAGAN, Minn., Sept. 28, 2017 (GLOBE NEWSWIRE) -- Biothera Pharmaceuticals, Inc. today announced that it will present new research at three upcoming healthcare conferences for Imprime PGG, Biothera’s...
July 19, 2017 10:00 ET | Source: Biothera Pharmaceuticals, Inc.

Biothera Pharmaceuticals Announces Initiation of Phase 1b/2 Clinical Study Evaluating Combination of Imprime PGG and Merck’s KEYTRUDA in Non-Small Cell Lung Cancer

EAGAN, Minn., July 19, 2017 (GLOBE NEWSWIRE) -- Biothera Pharmaceuticals, Inc. today announced that the Big Ten Cancer Research Consortium has begun patient dosing in a Phase 1b/2 clinical study to...
May 31, 2017 09:00 ET | Source: Biothera Pharmaceuticals, Inc.

Biothera Pharmaceuticals Announces Presentation at the Upcoming 2017 American Society of Clinical Oncology (ASCO) Annual Meeting

EAGAN, Minn., May 31, 2017 (GLOBE NEWSWIRE) -- Biothera Pharmaceuticals, Inc. announced today that a poster about the design of IMPRIME-1™, the company’s ongoing Phase 2 clinical trial in advanced...